UK becomes the first country to license a vaccine against COVID-19, creating the opportunity for mass immunization with Pfizer and BioNTech vaccine.

Vaccination will begin in the areas most at risk, the vaccine was authorized for emergency use by the Medicines and Healthcare Products Regulatory Authority, before US-Europe decisions.

The MHRA was given the power to approve the vaccine under special regulations, the first doses of the vaccine are expected to arrive in the coming days.  

Pfizer vaccine which has shown 95% efficacy in the final trials, was accepted for use.

After months of rigorous clinical trials and thorough analysis of the date by the expects at MHRA, concluded that the vaccine has met standards of safety, quality, and effectiveness.

The vaccine will be made available in the UK next week, will be available to priority groups like the elderly, care home residents, health and care staff, and those extremely vulnerable.  

800,000 doses are expected to arrive soon in the United Kingdoms, and the NHS stands ready to make it happen, as the first jabs require to be kept at -70c specialist centers are being built to store the doses at 50 hospitals, the vaccine can be stored at 2-8°C for five days.

And by next year 40million orders will be arriving in the country, each person is required to take two jabs.

The UK is confident the country would return to normal by the end of 2021, as reports indicate.

According to Pfizer and BioNTech, their combined manufacturing network has the potential to globally supply up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.

100 million ordered doses of US and 200 million doses Europe demand are expected to be distributed within a few weeks.

Pfizer and BioNTech formulated their vaccines based on the new technology messenger RNA or also known as mRNA.

Author

  • Mohammad Haroon Alim holds a BBA degree from Kardan University. He works as a sub-editor for Khaama Press.